Skip to content. | Skip to navigation

Personal tools

Sections
You are here: Home / Teams / Alternative splicing and tumoral progression - D. Auboeuf / Publications / A recently evolved class of alternative 3'-terminal exons involved in cell cycle regulation by topoisomerase inhibitors.

A recently evolved class of alternative 3'-terminal exons involved in cell cycle regulation by topoisomerase inhibitors.

Martin Dutertre, Fatima Z Chakrama, Emmanuel Combe, Francois-Olivier Desmet, Hussein Mortada, Micaela Polay Espinoza, Lise Gratadou, and Didier Auboeuf (2014)

Nat Commun, 5:3395.

Alternative 3'-terminal exons, which use intronic polyadenylation sites, are generally less conserved and expressed at lower levels than the last exon of genes. Here we discover a class of human genes, in which the last exon appeared recently during evolution, and the major gene product uses an alternative 3'-terminal exon corresponding to the ancestral last exon of the gene. This novel class of alternative 3'-terminal exons are downregulated on a large scale by doxorubicin, a cytostatic drug targeting topoisomerase II, and play a role in cell cycle regulation, including centromere-kinetochore assembly. The RNA-binding protein HuR/ELAVL1 is a major regulator of this specific set of alternative 3'-terminal exons. HuR binding to the alternative 3'-terminal exon in the pre-messenger RNA promotes its splicing, and is reduced by topoisomerase inhibitors. These findings provide new insights into the evolution, function andmolecular regulation of alternative 3'-terminal exons.

 
automatic medline import

Document Actions